Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs

Survey of Ophthalmology

Volumn 47, Issue 4 SUPPL. 1, 2002, Pages

  Eisenberg, Dan L ^a   Toris, Carol B ^b,c   Camras, Carl B ^b  

^a Shepherd Eye Center   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bimatoprost; Glaucoma; Intraocular pressure; Latanoprost; Ocular hypertension; Timolol; Travoprost

Indexed keywords

BIMATOPROST; EYE DROPS; LATANOPROST; PRODRUG; PROSTAGLANDIN F2 ALPHA DERIVATIVE; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

AQUEOUS HUMOR FLOW; BLOOD PRESSURE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONJUNCTIVA DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXFOLIATION SYNDROME; EYE COLOR; EYELASH; GLAUCOMA; HEADACHE; HEART RATE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; META ANALYSIS; NONHUMAN; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PRURITUS; REVIEW; SENSATION; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036668996     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00327-2     Document Type: Article

References (52)

1. Alm A., Camras C.B., Watson P.G. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 41(Suppl):1997;S105-S110.
2. Alm A., Stjernschantz J., the Scandinavian Latanoprost Study Group Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology. 102:1995;1743-1752.
3. Alm A., Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol. 109:1991;1564-1568.
4. Brandt J.D., VanDenburgh A.M., Chen K.et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP. a 3-month clinical trial Ophthalmology. 108:2001;1023-1031.
5. Brubaker R.F., Schoff E.O., Nau C.B.et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 131:2001;19-24.
6. Campbell RC: Statistics for Biologists. Cambridge, Cambridgeshire, Cambridge University Press, 1989, ed 3
7. Camras C.B. Bimatoprost vs. timolol. Ophthalmology. 109:2002;627-628. [letter].
8. Camras C.B. Travoprost compared with latanoprost and timolol in patients with open angle glaucoma or ocular hypertension. Am J Ophthalmol. 133:2002;732. [letter].
9. Camras C.B., Minckler D. Does that drug work? Pitfalls in studies on the efficacy and safety of glaucoma medications. Am J Ophthalmol. 129:2000;87-89.
10. 2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology. 96:1989;1329-1337.
11. Camras C.B., the United States Latanoprost Study Group Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology. 103:1996;138-147.
12. Camras C.B., Wax M.B., Ritch R.et al. Latanoprost treatment for glaucoma. effects of treating for 1 year and of switching from timolol Am J Ophthalmol. 126:1998;390-399.
13. Coleman R.A., Kennedy I., Sheldrick R.L. New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptors. Adv Prostaglandin Thromboxane Leukot Res. 17A:1987;467-470.
14. Colton T: Statistics in Medicine. Boston, MA, Little, Brown and Company, 1974, ed 1
15. 2α on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res. 6:1987;1035-1044.
16. DuBiner H., Cooke D., Dirks M.et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure. a 30-day comparison with latanoprost Surv Ophthalmol. 45:2001;S353-S360.
17. Dukes M., Russell W., Walpole A.L. Potent luteolytic agents related to prostaglandin F2alpha. Nature. 250:1974;330-331.
18. Fleiss J.L. Statistical Methods for Rates and Proportions. 1981;John Wiley & Sons, New York. ed 2.
19. Gandolfi S., Simmons S.T., Sturm R.et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 18:2001;110-121.
20. Goldberg I., Cunha-Vaz J., Jakobsen J.E.et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 10:2001;414-422.
21. Hedman K., Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 10:2000;95-104.
22. Hellberg M.R., McLaughlin M.A., Sharif N.A. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 47(Suppl 1):2002;S13-S33.
23. Hellberg M.R., Sallee V.L., McLaughlin M.A.et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 17:2001;421-432.
24. Johnstone M.A. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 124:1997;544-547.
25. Ke T.L., Graff G., Spellman J.M., Yanni J.M. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation. II. In vitro bioactivation and permeation of external ocular barriers Inflammation. 24:2000;371-384.
26. 2α-1-isopropyl ester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol. 105:1988;30-34.
27. Laibovitz R.A., VanDenburgh A.M., Felix C.et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol. dosing, efficacy, and safety evaluation of a novel compound for glaucoma management Arch Ophthalmol. 119:2001;994-1000.
28. Mastropasqua L., Carpineto P., Ciancaglini M., Gallenga P.E. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 106:1999;550-555.
29. Matsuda S., Kanemitsu N., Nakamura A.et al. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp Eye Res. 64:1997;707-711.
30. Maxey K.M., Johnson J., LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 47(Suppl 1):2002;S34-S40.
31. Mishima H.K., Kiuchi Y., Takamatsu M.et al. Circadian intraocular pressure management with latanoprost. diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow Surv Ophthalmol. 41:1997;S139-S144.
32. Mishima H.K., Masuda K., Kitazawa Y.et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12 week study. Arch Ophthalmol. 114:1996;929-932.
33. Netland P.A., Landry T., Sullivan E.K.et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 132:2001;472-484.
34. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 48:1989;707-716.
35. Pate D.W., Jarvinen K., Urtti A.et al. Effects of topical anandamides on intraocular pressure in normotensive rabbits. Life Sci. 58:1996;1849-1860.
36. Resul B., Stjernschantz J., No K.et al. Phenyl-substituted prostaglandins. potent and selective antiglaucoma agents J Med Chem. 36:1993;243-248.
37. Resul B., Stjernschantz J., Selén G., Bito L.Z. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol. 41:1997;S47-S52.
38. Sakurai M., Araie M., Oshika T.et al. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 35:1991;156-165.
39. Sharif N.A., Williams G.W., Kelly C.R. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 432:2001;211-213.
40. Sherwood M., Brandt J., for the Bimatoprost Study Groups 1 and 2 Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 45:2001;S361-S368.
41. Stjernschantz J., Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future. 17:1992;691-704.
42. 2α-isopropyl ester to latanoprost. a review of the development of Xalatan: the Proctor Lecture Invest Ophthalmol Vis Sci. 42:2001;1134-1145.
43. Tetsuka H., Tsuchisaka H., Kin K.et al. A mechanism for reducing intraocular pressure in normal volunteers using UF-021, a prostaglandin-related compound. Nippon Ganka Gakkai Zasshi. 96:1992;496-500.
44. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology. 100:1993;1297-1304.
45. Toris C.B., Camras C.B., Yablonski M.E., Brubaker R.F. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 41:1997;S69-S75.
46. Toris CB, Zhan G, Camras CB, McLaughlin MA: Travoprost Increases Uveoscleral Outflow in Monkeys. ARVO Abstract #1970, 2002
47. 2α-isopropylester eye drops. effects in normal human eyes Br J Ophthalmol. 73:1989;419-426.
48. Watson P., Stjernschantz J., the Latanoprost Study Group A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 103:1996;126-137.
49. Weinreb R.N., Toris C.B., Gabelt B.T.et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 47(Suppl 1):2002;S53-S64.
50. Woodward D.F., Krauss A.H.P., Chen J.et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 45:2001;S337-S345.
51. Zhang W.Y., Po A.L.W., Dua H.S., Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 85:2001;983-990.
52. 2alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 111:1993;1351-1358.